EquiReason

EquiReason research coverage

Zymeworks Inc. ZYME

Healthcare · Biotechnology

22quarters analysed
12SEC filings read
5segments identified
9institutional managers tracked

Segments it reports

The business segments Zymeworks Inc. reports in its own SEC filings.

  • Reportable Segment

Product lines it reports

The product and service lines Zymeworks Inc. breaks its revenue into.

  • Milestone Revenue
  • Recognition Of Deferred Revenue
  • Option Exercise Fee
  • Drug Supply For Ongoing Studies
  • Research Support Payments And Other Service
  • Drug Supply
  • Royalty
  • Research Period Extension Fee

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements26
  • Quarterly metric series12
  • Business segments5
  • SEC filings12
  • Deals and transactions3
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks4
  • Estimate revisions11
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series20
  • Cash flow series19
  • Earnings series22
  • Operating cash flow series19
  • Guidance changesnot found
  • Margin seriesnot found
  • Per-share seriesnot found

This page says how much of Zymeworks Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open ZYME in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Zymeworks Inc. (ZYME) — research coverage | EquiReason